Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The latest news, stories and exciting findings from across the Oxford cancer research community

University's RadCam library highlighted in yellow

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also also correctly identified the original site of cancer in 85% of those cases.

Oxford DeLIVER research attracts 1000 patients for innovative Pearl clinical study

1000 patients have been recruited for the Pearl study within the DeLIVER programme.

Project submissions for the DPhil in Cancer Science now open!

The DPhil in Cancer Science is inviting project submissions from Oxford-based PIs across medical, physical, engineering, data, and mathematical sciences for its 2024 intake.

Royal Society elects eight Oxford scientists as new Fellows

Eight academics from the University of Oxford have joined the Royal Society as Fellows, including Professor Michael Dustin FRS, Kennedy Trust Professor of Molecular Immunology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) and Director of Research at the Kennedy Institute of Rheumatology.

Eight Oxford researchers become Fellows of the Academy of Medical Sciences

The Academy of Medical Sciences has elected eight University of Oxford biomedical and health scientists to its fellowship.

Patient and Public Involvement profile: In conversation with Sally Jeans

Involving patients and the public in cancer research can help to guide the direction of medical research in a way that benefits those that need it most.

Monica Olcina receives Academy of Medical Sciences Springboard Award

Monica is one of 40 recipients of the 2023 Springboard Award, which is awarded to biomedical and health researchers in their first independent post to help launch their careers.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer is pleased to announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation.

Edward O'Neill wins Prostate Cancer UK Career Acceleration Fellowship

Dr Edward O'Neill will is to join Oxford University's Nuffield Department of Surgical Sciences after securing a prestigious Prostate Cancer UK Career Acceleration Fellowship.

Four Oxford researchers awarded €2.5 million European Research Council Advanced Grants

Four University of Oxford researchers have been awarded European Research Council (ERC) Advanced Grants of €2.5 million each over five years to explore their most innovative and ambitious ideas. These grants recognise ground-breaking projects led by researchers with a track record of significant research achievements.

New tool uses health records to predict risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed ‘CanPredict’, a new tool able to identify those most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and lives.

New work unpicks key cancer development pathway

Work led by Dr Anna Rose and DPhil student Tomas Goncalves has unpicked a key DNA interaction that leads cells to become cancerous via a particular pathway that causes up to 80% of the cancers affecting children and young people.

Any type of hormonal contraceptive may increase risk of breast cancer

An analysis of data by researchers at Oxford Population Health’s Cancer Epidemiology Unit has shown that use of progestogen-only hormonal contraceptives is associated with a 20-30% higher risk of breast cancer. The results are published today in PLOS Medicine.

Mark Hill becomes Fellow of the Institute of Physics and Engineering in Medicine

Dr Mark Hill was awarded the honour of Fellow of the Institute of Physics and Engineering in Medicine (FIPEM) after ‘demonstrating scientific and professional attainment of outstanding merit’. Mark has over 35 years of experience in the field of radiation biology and physics, spanning basic, pre-clinical and clinically related research.

Study shows delaying treatment for localised prostate cancer does not increase mortality risk

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind.

Prostate cancer AI diagnosis tool begins evaluation in Oxford

Researchers and clinicians in Oxford have begun an evaluation of artificial intelligence (AI) software that could help pathologists diagnose prostate cancer.

Key exosome subtype in cancer progression identified

Collaborative work from the Department of Physiology, Anatomy and Genetics and the Department of Oncology has revealed a potential new pathway to block the production of a specific group of exosomes made in the cell’s recycling system that can promote the growth of cancerous tumours.

Inequalities in COVID-19 vaccine uptake remain among people with blood cancers

People with blood cancers are among the most clinically vulnerable individuals to COVID-19 in the UK. Despite this, vaccine uptake has decreased with each subsequent dose, according to new research from the Nuffield Department of Primary Care Health Sciences.

New research opens new strategies for cancer therapeutics

Researchers from the Nuffield Department of Medicine’s Target Discovery Institute and CAMS Oxford Institute, and the Department of Biochemistry uncovered at the molecular level how protein BIRC6 (a giant ubiquitin ligase) keeps cells alive.

NCRI appoints Professor Tim Maughan as new interim CEO

The National Cancer Research Institute (NCRI) has announced that Professor Tim Maughan, Emeritus Professor of Clinical Oncology, has been appointed their new Interim CEO.

Load More